Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Antibody Drug Conjugates Market by Product [Adcetris (Brentuximab vedotin), Aidixi (Disitamab vedotin), Akalux (Cetuximab sarotalocan), Besponsa (Inotuzumab ozogamicin), Blenrep (Belantamab mafodotin), Enhertu (Trastuzumab deruxtecan), Kadcyla (Trastuzumab emtansine), Lumoxiti (Moxetumomab pasudotox), Mylotarg (Gemtuzumab ozogamicin), Padcev (Enfortumab vedotin), Polivy (Polatuzumab vedotin), Tivdak (Tisotumab vedotin), Trodelvy (Sacituzumab govitecan), Zynlonta (Loncastuximab tesirine), Pipiline Analysis and Forecast 2024-2031

$3,000.00

Report Specifications: Market Size, Market Share, Growth Trends, Forecast, Geography

Antibody drug conjugates (ADCs) consist of recombinant monoclonal antibodies (mAbs) that are covalently bound to cytotoxic chemicals via synthetic linkers. ADCs take advantage of the specificity of mAbs to deliver potent cytotoxic drugs selectively to antigen-expressing tumor cells. Antibody drug conjugates are one of the fastest growing classes of oncology therapeutics.

In 2011, Seattle Genetics/Takeda’s Adcetris (brentuximab vedotin) was approved for treating Hodgkin lymphoma and anaplastic large cell lymphoma, whereas in 2013, Roche’s Kadcyla (trastuzumab emtansine) was approved for the treatment of breast cancer. The approvals have paved the way for ongoing clinical trials that are evaluating more than 60 further ADC candidates. The limited success of first-generation

ADCs led second-generation ADCs to the market, which have higher levels of cytotoxic drug conjugation, lower levels of naked antibodies and more-stable linkers between the drug and the antibody. Later, the lessons learned during the past decade are now being used in the development of third-generation ADCs, which involved strategies to select the best target antigens as well as suitable cytotoxic drugs; the design of optimized linkers; the discovery of bioorthogonal conjugation chemistries; and toxicity issues.

Advancements over the past several decades have led to a new generation of ADCs comprising non-immunogenic mAbs, linkers with balanced stability and highly potent cytotoxic agents. In the recent years, ADC development platforms have matured sufficiently for multiple ADCs to gain regulatory approval, with several also close to market and a deep pipeline in development. In addition to the FDA-approved ADCs, there are several compounds are in late-stage clinical testing for both hematological and solid tumor indications.

The global antibody drug conjugates market segmentation is based on product [Adcetris (Brentuximab vedotin), Aidixi (Disitamab vedotin), Akalux (Cetuximab sarotalocan), Besponsa (Inotuzumab ozogamicin), Blenrep (Belantamab mafodotin), Enhertu (Trastuzumab deruxtecan), Kadcyla (Trastuzumab emtansine), Lumoxiti (Moxetumomab pasudotox), Mylotarg (Gemtuzumab ozogamicin), Padcev (Enfortumab vedotin), Polivy (Polatuzumab vedotin), Tivdak (Tisotumab vedotin), Trodelvy (Sacituzumab govitecan), Zynlonta (Loncastuximab tesirine), pipeline pnalysis, and geography.

The global antibody drug conjugates market research report provides market size ($Million 2021 to 2031), market share analysis, growth trends and forecast (CAGR%, 2024 to 2031).

The global antibody drug conjugates market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

In addition, the global antibody drug conjugates market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries.  The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global antibody drug conjugates market and profiled in this report include ADC Therapeutics S.A., Astellas Pharma, Inc., AstraZeneca plc, Daiichi Sankyo Co. Ltd., Gilead Sciences, Inc. (Immunomedics, Inc.), GlaxoSmithKline plc, Innate Pharma S.A., Pfizer, Inc., Rakuten Medical, Inc., RemeGen Co., Ltd. (RemeGen Biosciences), Roche Holding AG, Seagen, Inc. (Seattle Genetics, Inc.), and Takeda Pharmaceutical Co. Ltd.

DATA INCLUDED: Antibody Drug Conjugates Market Size, Antibody Drug Conjugates Market Share, Antibody Drug Conjugates Market Growth Rates, Antibody Drug Conjugates Market Trends, and Antibody Drug Conjugates Market Forecast to 2031

Market Data:

  • Base year for estimation: 2023
  • Actual estimates/Historical data: 2021-2031
  • Forecast period: 2024-2031
  • Market representation: Revenue in $million and CAGR % from 2024 to 2031
  • Regional scope: North America, Europe, Asia Pacific, Latin America, Rest of the World (Middle East & Africa)
  • Country scope: U.S., Canada, U.K., Germany, France, Italy, Spain, Japan, China, India, South Korea, Brazil, Mexico, South Africa, South Korea, Saudi Arabia, UAE and others.
  • Report coverage: Revenue forecast, company share, competitive landscape, growth factors, and trends
  • 15% free customization scope: Any specific or custom requirements, which is not currently within the scope of the report, will be provided as a part of customization.

Qualitative Analysis:

  • Industry overview
  • Industry trends
  • Market drivers and restraints
  • Key market opportunities
  • Market size
  • Growth trends
  • Porter’s five forces analysis
  • Market attractiveness analysis
  • Competitive landscape
    • Company overview
    • Financial performance
    • Product portfolio
    • Strategic insights
    • Recent developments

Quantitative Analysis:

  • Market size estimates and forecast for all segments
  • Regional market size estimated and forecast for major countries
  • Company financial performance
  • Competitive landscape: Company market share analysis

Please contact us for offers on individual or multiple report purchases.

  1. Introduction
  2. Executive Summary
    • Market Size Estimation ($million, 2021-2031)
    • Forecast Estimation ($million and CAGR%, 2024-2031)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Products
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Product Type (cells, media, serum, vaccine, protein, instrument, etc.)
    • Source Type
    • Reagents and Consumables Type
    • Diagnostic Test
    • Indication Type
    • Technology
    • Diagnostics, Therapeutic or Surgical Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World (Middle East & Africa)
  7. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  8. Recommendations
  9. References

Key Questions Answered:
1. What are the factors driving and limiting this market, key success factors and challenges?
2. Which are the leading competitors in the market, their market share, profitability and key trends by product, technology, services portfolio?
3. How do markets perform between countries and regions?
4. What market segments are contributing to maximum share and greatest growth?
5. What are the product or procedure volumes by country and regions?

Actionable Insights Included:
1. Product portfolio matrix (Share vs. Growth)
2. Market attractiveness (Region vs. Growth)
3. Spot matrix (Product vs. Region)
4. Geographic distribution matrix (Share vs. Growth)

Antibody Drug Conjugates Market

1. Product
1.1. Adcetris (Brentuximab vedotin)
1.2. Aidixi (Disitamab vedotin)
1.3. Akalux (Cetuximab sarotalocan)
1.4. Besponsa (Inotuzumab ozogamicin)
1.5. Blenrep (Belantamab mafodotin)
1.6. Enhertu (Trastuzumab deruxtecan)
1.7. Kadcyla (Trastuzumab emtansine)
1.8. Lumoxiti (Moxetumomab pasudotox)
1.9. Mylotarg (Gemtuzumab ozogamicin)
1.10. Padcev (Enfortumab vedotin)
1.11. Polivy (Polatuzumab vedotin)
1.12. Tivdak (Tisotumab vedotin)
1.13. Trodelvy (Sacituzumab govitecan)
1.14. Zynlonta (Loncastuximab tesirine)

2. Pipeline Analysis (Phase II and III)

3. Geography
3.1. North America (U.S., Canada)
3.2. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.3. Asia Pacific (Japan, China, India, Rest of APAC)
3.4. Latin America (Brazil, Mexico, Rest of LA)
3.5. Rest of the World

4. Company Profiles
4.1. ADC Therapeutics S.A.
4.2. Astellas Pharma, Inc.
4.3. AstraZeneca plc
4.4. Daiichi Sankyo Company Limited
4.5. Gilead Sciences, Inc. (Immunomedics, Inc.)
4.6. GlaxoSmithKline plc
4.7. Innate Pharma S.A.
4.8. Pfizer, Inc.
4.9. Rakuten Medical, Inc.
4.10. RemeGen Co., Ltd. (RemeGen Biosciences)
4.11. Roche Holding AG
4.12. Seagen, Inc. (Seattle Genetics, Inc.)
4.13. Takeda Pharmaceutical Co. Ltd.

    Request ToC / Sample Report

    Full Name*

    Company Email*

    Phone Number* [Please add country code]

    Subject*

    Message*

    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com